The Scientist

» colonists and disease/medicine

Most Recent

image: Cancer Drug Flushes Out HIV

Cancer Drug Flushes Out HIV

By | July 26, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

1 Comment

image: Modeling the Cell

Modeling the Cell

By | July 23, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

2 Comments

image: One Million Genomic Datasets

One Million Genomic Datasets

By | July 23, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

2 Comments

image: Mosquito Gut Bacteria to Fight Malaria

Mosquito Gut Bacteria to Fight Malaria

By | July 17, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

0 Comments

image: Early Epigenetic Influence

Early Epigenetic Influence

By | July 16, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

8 Comments

image: Scorpion Venom Kills MRSA

Scorpion Venom Kills MRSA

By | July 12, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

2 Comments

image: Natural Alzheimer’s Protection

Natural Alzheimer’s Protection

By | July 11, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

0 Comments

image: Maps Show Animal Disease Hotspots

Maps Show Animal Disease Hotspots

By | July 6, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

0 Comments

image: DNA Methylation Linked to Memory Loss

DNA Methylation Linked to Memory Loss

By | July 2, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

5 Comments

image: DNA Truth or Dare

DNA Truth or Dare

By | July 1, 2012

An approved cancer therapeutic makes hiding HIV susceptible to antiviral therapy.

1 Comment

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech